课题基金 / 基金详情

Off-the-shelf engineered NK cells to treat glioblastoma

Off-the-shelf engineered NK cells to treat glioblastoma
现成的工程 NK 细胞用于治疗胶质母细胞瘤
批准号:
10481503
负责人:
Joe Trebley
金额:
$39.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-01 至 2024-07-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
项目总结 胶质母细胞瘤(GBM)是最致命的脑癌,超过12000人被诊断为 每年都会得这种病。目前的护理标准包括在可能的情况下进行手术,然后结合 化疗和放射治疗。不幸的是,治疗结果仍然很差,只有15%的患者 能存活5年以上。免疫疗法的最新进展,如CAR-T细胞疗法,已经成为 对其他癌症很有希望,但大量研究发现,在应用这些方法时存在几个障碍 对胶质母细胞瘤有效。特别是,GBM细胞具有高度的异质性,使它们能够逃避免疫。 检测,他们提供了一个免疫抑制微环境,降低了疗效 免疫疗法。此外,工程化的T细胞在来源上面临挑战,因为它们引发了强大的移植物抗... 宿主疾病反应。Monon BioVentures与普渡大学的马托舍维奇博士合作, 开发一种免疫疗法,解决以前方法的局限性。我们设计了一部小说 三重特异性CAR-NK细胞能够通过多种特定机制克服这些障碍- 改善肿瘤浸润性和局部反应性靶向活性,同时克服多种机制 免疫抑制。此外,NK细胞不需要严格的供受者匹配,可以 现成的。对三重特异性CAR-NK细胞的初步研究表明对GBM细胞具有有效的杀伤作用 在试管中。此外,对GBM异种移植小鼠的体内研究表明,肿瘤侵袭增加,肿瘤减少 增长和提高存活率。Monon BioVentures正在将这种有希望的疗法从实验室带到临床。 为了实现这一目标,我们建议开发一种可扩展的方法来使用NK细胞来生产CAR-NK细胞 从血液中提取,并在GBM异种移植模型中证明了治疗效果。以下是 具体目的:目的1.从脐带血中分离NK细胞并对其进行特性鉴定。这将是 通过两个子任务进行:目标1 A.在一个 支持GMP的设施,通过与cGMP一致的可扩展方法验证媒介生产 标准。目标1B。从脐带血中分离和转导NK细胞;测定转导效率和 描述CAR-NK细胞的功能。目的2.证明CAR-NK在患者来源的GBM中的疗效 异种移植小鼠模型。该项目将生成B类预审会议所需的结果 美国食品和药物管理局。根据FDA的反馈,第二阶段的资金将用于支持开始 第一阶段试验。一旦开发出来,我们基于CAR-NK的新疗法有可能建立一种亟需的 为那些患有GBM的人提供新的护理标准,并可显著改善疾病的结局。
英文摘要
PROJECT SUMMARY Glioblastoma (GBM) is the most lethal form of brain cancer and more than 12,000 people are diagnosed with this disease every year. Current standard of care involved surgery where possible, followed by a combination of chemotherapy and radiotherapy. Unfortunately, the outcome of treatment remains poor with only 15% of patients surviving beyond 5 years. Recent advances in immunotherapy, such as CAR-T cell therapy, have been promising with other cancers but numerous studies have identified several hurdles in applying these methods effectively to glioblastoma. Particularly, GBM cells have high heterogeneity allowing them to escape immune detection, and they present an immunosuppressive microenvironment which reduces the efficacy of immunotherapies. Moreover, the engineered T cells are challenging to source as they elicit a strong graft-vs- host disease response. Monon Bioventures, in collaboration with Dr. Matosevic at Purdue University, is developing an immunotherapy that addresses the limitations of previous approaches. We have designed a novel triple-specific CAR-NK cell capable of overcoming these hurdles through multiple specific mechanisms – improved tumor infiltration and locally-responsive targeted activity while overcoming multiple mechanisms of immunosuppression. Additionally, NK cells do not require stringent donor-recipient matching and can be obtained off-the-shelf. Preliminary studies with the triple-specific CAR-NK cells show efficient killing of GBM cells in vitro. Further, in vivo studies with GBM xenografted mice show increased tumor infiltration, reduction in tumor growth and improved survival. Monon Bioventures is bringing this promising therapy from the lab to the clinic. To achieve this goal, we propose to develop a scalable method to produce the CAR-NK cells using NK cells sourced from blood and demonstrate the efficacy of the therapeutic in a GBM xenograft model. The following Specific Aims are planned: Aim 1. Engineer and characterize NK cells isolated from cord blood. This will be carried out through two sub-tasks: Aim 1 A. Recreate the novel lentiviral vector designed by Dr. Matosevic in a GMP-capable facility, validating vector production through scalable methods that are consistent with cGMP standards. Aim 1B. Isolate and transduce NK cells from cord blood; determine transduction efficiency and characterize functionality of the CAR-NK cells. Aim 2. Demonstrate efficacy of CAR-NK in a patient-derived GBM xenograft mouse model. This project will generate the results needed for a Type B Pre-IND meeting with the FDA. With feedback from the FDA, Phase II funding will go to support the IND package necessary to begin the Phase I trial. Once developed, our novel CAR-NK based therapy has the potential to establish a much-needed new standard of care for those suffering from GBM and could significantly improve the outcome of the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金